We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
+10.92%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$355M
AUM Growth
-$16.8M
(-4.5%)
Cap. Flow
-$17.7M
Cap. Flow
% of AUM
-4.99%
Top 10 Holdings %
Top 10 Hldgs %
50.26%
Holding
90
New
4
Increased
16
Reduced
25
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$9.25M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$4.36M |
| 3 |
Biohaven
BHVN
|
+$3.33M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$3.13M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
+$2.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$16.6M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
+$5.82M |
| 3 |
Adicet Bio
ACET
|
+$4.74M |
| 4 |
AERI
Aerie Pharmaceuticals
AERI
|
+$4.65M |
| 5 |
ETNB
89bio
ETNB
|
+$2.98M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.98% |
| 2 | Miscellaneous | 17.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
State Street SPDR S&P Biotech ETF
XBI
$11.3B
| $47M | 13.23% |
566,000
| – | – |
|
2
Stereotaxis
STXS
$145M
| $28.3M | 7.98% |
13,680,554
| – | – |
|
3
Ascendis Pharma A/S
ASND
$16.3B
| $15.9M | 4.48% |
130,212
-5,500
| -4% | -$639K |
|
|
KRTX
4
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $14.2M | 3.99% |
72,027
+43,141
| +149% | +$9.25M |
|
5
iShares Biotechnology ETF
IBB
$10.5B
| $13.5M | 3.79% |
102,500
| – | – |
|
|
ISEE
6
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $13M | 3.65% |
605,975
+204,499
| +51% | +$4.36M |
|
7
Xenon Pharmaceuticals
XENE
$5.81B
| $12.5M | 3.51% |
316,092
-59,131
| -16% | -$2.15M |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $11.4M | 3.22% |
261,235
| – | – |
|
9
Revolution Medicines
RVMD
$44.6B
| $11.4M | 3.21% |
477,785
-2,000
| -0.4% | -$42.5K |
|
|
10
Syndax Pharmaceuticals
SNDX
$1.74B
| $11.4M | 3.2% |
447,073
+91,586
| +26% | +$2.14M |
|
11
Neurocrine Biosciences
NBIX
$15.7B
| $8.73M | 2.46% |
73,121
-7,034
| -9% | -$824K |
|
12
IDEAYA Biosciences
IDYA
$3.87B
| $8.51M | 2.4% |
468,358
-70,203
| -13% | -$1.18M |
|
13
Cytokinetics
CYTK
$10B
| $8.43M | 2.37% |
183,995
| – | – |
|
14
DexCom
DXCM
$34.3B
| $7.65M | 2.15% |
67,552
-5,000
| -7% | -$549K |
|
|
SAGE
15
DELISTED
Sage Therapeutics
SAGE
| $6.88M | 1.94% |
180,306
| – | – |
|
16
Edgewise Therapeutics
EWTX
$4.64B
| $6.86M | 1.93% |
766,843
-14,269
| -2% | -$134K |
|
17
Nurix Therapeutics
NRIX
$2.72B
| $6.22M | 1.75% |
566,695
| – | – |
|
|
18
Adicet Bio
ACET
$84.8M
| $5.65M | 1.59% |
39,472
-19,013
| -33% | -$4.74M |
|
19
Fate Therapeutics
FATE
$291M
| $5.56M | 1.57% |
550,940
+11,000
| +2% | +$207K |
|
|
20
Biohaven
BHVN
$2.33B
| $5.46M | 1.54% |
393,113
+236,017
| +150% | +$3.33M |
|
|
MORF
21
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $5.23M | 1.47% |
195,467
| – | – |
|
22
Alector
ALEC
$261M
| $4.91M | 1.38% |
532,438
| – | – |
|
23
Viking Therapeutics
VKTX
$3.75B
| $4.9M | 1.38% |
521,553
-30,847
| -6% | -$138K |
|
|
APLS
24
DELISTED
Apellis Pharmaceuticals
APLS
| $4.31M | 1.22% |
83,446
+17,500
| +27% | +$928K |
|
|
MRUS
25
DELISTED
Merus
MRUS
| $4.18M | 1.18% |
269,893
-7,000
| -3% | -$123K |
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, DAFNA Capital Management held 90 positions worth $355M, down 4.5% from $372M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
DAFNA Capital Management withdrew a net $17.7M in Q4 2022, closing 11 positions and reducing 25 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $16.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 84% a quarter earlier, followed by Miscellaneous.
Against the trend, DAFNA Capital Management opened a new position in BioCryst Pharmaceuticals worth $2.88M.
- DAFNA Capital Management's largest Q4 2022 buy was BioCryst Pharmaceuticals: 251,000 shares worth $2.88M.
- DAFNA Capital Management added most to Karuna Therapeutics, Inc. Common Stock in Q4 2022, an estimated $9.25M increase.
- DAFNA Capital Management's biggest Q4 2022 reduction was Cymabay Therapeutics, cutting an estimated $5.82M.
- DAFNA Capital Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $16.6M.
- DAFNA Capital Management's ten largest holdings make up 50% of its $355M portfolio in Q4 2022.
- DAFNA Capital Management opened 4 new positions and closed 11 in Q4 2022.
- DAFNA Capital Management's portfolio value fell 4.5% quarter-over-quarter to $355M.
Based on DAFNA Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.